Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06391996
Status:
COMPLETED
Last Update Posted:
2024-04-30
First Post:
2024-04-20
Brief Title:
Biologic Therapy for Generalized Pustular Psoriasis
Sponsor:
Chao Ji
Organization:
First Affiliated Hospital of Fujian Medical University
Study Overview
Official Title:
Genetics-based Efficacy Analysis Ustekinumab Versus Secukinumab for the Treatment of Generalized Pustular Psoriasis
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators aim to compare the efficacy and safety of secukinumab and ustekinumab in patients with generalized pustular psoriasis GPP and to explore the impact of genetic mutation types on clinical efficacy The main questions the study aims to answer are
Is there a difference in the effectiveness of secukinumab and ustekinumab in the treatment of GPP How is the safety of secukinumab and ustekinumab in the treatment of GPP Does the type of genetic mutation in GPP patients affect the efficacy of secukinumab and ustekinumab The investigators will compare patients treated with secukinumab to those treated with ustekinumab to see the difference in the effectiveness of the two drugs in treating GPP
Participants will
The investigators conducted a 48-week follow-up study on 65 participants who were admitted to the dermatology department of the First Affiliated Hospital of Fujian Medical University for GPP from July 2019 to December 2022 All participants underwent saliva-based genetic testing
Efficacy analyses were performed based on the scores of Generalized Pustular Psoriasis Area and Severity Index GPPASI and Generalized Pustular Psoriasis Physician Global Assessment GPPGA at week 0 2 4 12 24 and 48
Participants were also asked to report all adverse events AEs during follow-up
Is there a difference in the effectiveness of secukinumab and ustekinumab in the treatment of GPP How is the safety of secukinumab and ustekinumab in the treatment of GPP Does the type of genetic mutation in GPP patients affect the efficacy of secukinumab and ustekinumab The investigators will compare patients treated with secukinumab to those treated with ustekinumab to see the difference in the effectiveness of the two drugs in treating GPP
Participants will
The investigators conducted a 48-week follow-up study on 65 participants who were admitted to the dermatology department of the First Affiliated Hospital of Fujian Medical University for GPP from July 2019 to December 2022 All participants underwent saliva-based genetic testing
Efficacy analyses were performed based on the scores of Generalized Pustular Psoriasis Area and Severity Index GPPASI and Generalized Pustular Psoriasis Physician Global Assessment GPPGA at week 0 2 4 12 24 and 48
Participants were also asked to report all adverse events AEs during follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None